[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-hepatocellular-carcinoma-hcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-hepatocellular-carcinoma-hcc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,48,79,101,123,161,182,208,232,256,277,299,319,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100572795","phase-2-hai-or-iv-of-adebrelimab-combined-with-bevacizumab-and-hai-of-folfox-for-advanced-unresectable-hepatocellular-carcinoma-100572795",false,"NCT06737913","HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","Hepatic Arterial Infusion or Intravenous Infusion of Adebrelimab, Combined With Bevacizumab and Hepatic Arterial Infusion of FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma: a Multicenter, Open Label, Randomized Phase II Trial","HAIBrave-001","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the informed consent form;\n2. Aged ≥18 years (calculated as of the date of signing the informed consent form);\n3. Diagnosed with hepatocellular carcinoma (HCC) by clinical or pathological means;\n4. Barcelona Clinic Liver Cancer (BCLC) stage C, with vascular\u002Fbile duct invasion or distant metastasis (excluding cases with Vp4-type tumor thrombus);\n5. No prior systemic therapy for HCC; or progression or residual lesions following prior local therapy for HCC (including but not limited to surgery, ablation, radiotherapy, or transarterial chemoembolization \\[TACE\\]), with an interval of at least one month between the last local treatment and enrollment;\n6. ECOG Performance Status (PS) score of 0-1 and Child-Pugh grade A or grade B with a score of 7;\n7. No history of autoimmune disease;\n8. An expected survival time of ≥3 months;\n9. At least one measurable lesion (per RECIST v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan must be ≥10 mm or the short axis of enlarged lymph nodes must be ≥15 mm; lesions previously treated locally can be considered target lesions if progression is confirmed per RECIST v1.1 criteria);\n10. Sufficient hematologic, hepatic, and renal function, with laboratory tests within the following parameters performed within one week prior to enrollment:\n\n    * Neutrophil count ≥1.5×10\\^9\u002FL;\n\n      * Platelet count ≥75×10\\^9\u002FL;\n\n        * Hemoglobin ≥90 g\u002FL;\n\n          * Serum ALT and AST ≤5×upper limit of normal (ULN); ⑤ Serum creatinine ≤1.5×ULN; ⑥ International Normalized Ratio (INR) \\\u003C2.3, or prothrombin time ≤ULN+6 seconds; ⑦ Albumin ≥30 g\u002FL;\n\n            * Total bilirubin ≤3×ULN.\n11. Women of childbearing potential must have a negative serum or urine pregnancy test within seven days prior to study enrollment, must not be breastfeeding, and must agree to use contraceptive measures during the study and for six months after its conclusion; men must agree to use contraceptive measures during the study and for six months after its conclusion.\n\nExclusion Criteria:\n\n1. Patients with a severe allergy to iodine contrast agents who are unable to undergo hepatic arterial infusion chemotherapy (HAIC);\n2. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within one month prior to randomization;\n3. Active infections that cannot be effectively controlled;\n4. Severe gastroesophageal varices; untreated or incompletely treated gastroesophageal varices (with bleeding or high risk of bleeding);\n5. Presence of brain metastases or bone metastases requiring urgent surgical or radiotherapy intervention;\n6. Pregnant or suspected to be pregnant, or currently breastfeeding;\n7. Current use or recent use (within 10 days before the initiation of the study treatment) of aspirin (\\>325 mg\u002Fday, maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;\n8. Thrombotic or embolic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, or cerebral infarction) or pulmonary embolism, occurring within six months prior to the initiation of the study treatment;\n9. Congenital or acquired immunodeficiency;\n10. History of other malignant tumors;\n11. Any of the following conditions within 12 months prior to the initiation of the study: myocardial infarction, severe\u002Funstable angina, or congestive heart failure;\n12. Renal insufficiency requiring dialysis;\n13. History of organ transplantation;\n14. Severe acute or chronic physical or mental illnesses or laboratory abnormalities that may increase study risks or interfere with result interpretation, rendering the patient unsuitable for enrollment.","ALL","18 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.",[27],"Advanced Hepatocellular Carcinoma (HCC)",[29,30,31,32,33,34],"Hepatic arterial infusion (HAI)","hepatic arterial infusion of FOLFOX chemotherapy","advanced unresectable hepatocellular carcinoma (HCC)","Adebrelimab (ADE)","Bevacizumab (Bev.)","intravenous infusion (IV)","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2025-01-03",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Sun Yat-sen University","OTHER",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100630851","phase-1-an-open-label-phase-i-clinical-trial-of-super-car-t-with-gpc3-positive-advanced-hepatocellular-carcinoma-100630851","NCT07493044","An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form prior to participating in any trial-related activities;\n2. Be between 18 and 75 years of age; gender is not restricted;\n3. Diagnosed with hepatocellular carcinoma (HCC) based on histopathological or cytological examination: Patients classified as inoperable Stage IIa, IIb, IIIa, or IIIb according to the Chinese National Liver Cancer (CNLC) staging system, or Stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system, or Stage B patients who are inoperable or unsuitable for local treatment; Child-Pugh liver function score ≤ 7;\n4. Previous failure of or intolerance to at least two lines of standard systemic therapy;\n5. The subject must provide a tumor sample or biopsy specimen collected within the past 2 years that meets the requirements and tests positive for GPC3 expression via immunohistochemistry;\n6. At least one measurable lesion according to RECIST 1.1 criteria;\n7. ECOG performance status of 0-1;\n8. Expected survival of more than 3 months;\n9. Echocardiography showing a left ventricular ejection fraction (LVEF) ≥50%;\n10. Laboratory test results must meet at least the following criteria:\n\n    ANC ≥1.0×10⁹\u002FL; PLT ≥75×10⁹\u002FL; Hb ≥ 75 g\u002FL; Creatinine clearance ≥ 60 mL\u002Fmin; AST ≤ 5×ULN; ALT≤ 5×ULN; TBIL ≤ 3×ULN;\n11. If HBsAg-positive or HBcAb-positive, HBV-DNA must be ≤ 2000 IU\u002FmL;\n12. Women of childbearing potential must have a negative pregnancy test prior to receiving study treatment; they must agree to use effective contraception during treatment.\n\nExclusion Criteria:\n\n1. The subject has undergone major surgery within 2 weeks prior to apheresis, or is expected to undergo major surgery during the trial;\n2. The subject is allergic to any component of the drugs to be used in this study, including but not limited to cyclophosphamide, fludarabine, CAR-T products, or their excipients;\n3. Has not recovered from adverse reactions related to prior surgery or treatment to Grade ≤ 2; exceptions include alopecia, hyperpigmentation, and other conditions deemed by the investigator not to affect the subject's tolerability;\n4. Has a clinically significant central nervous system (CNS) disorder (e.g., epilepsy, severe cerebrovascular stenosis) or other diseases presenting with significant neurological symptoms (including psychiatric disorders);\n5. Received radiotherapy, systemic chemotherapy, or immune checkpoint inhibitors for the study disease within 2 weeks prior to apheresis; or received small-molecule targeted therapies such as sorafenib, regorafenib, or lenvatinib within 1 week prior to apheresis;\n6. Received systemic glucocorticoid therapy within 7 days prior to single-plasma donation; patients currently using or who have recently used inhaled or topical glucocorticoids, as well as those on physiological-dose replacement therapy, are eligible for enrollment;\n7. Any uncontrolled active infection, including but not limited to active tuberculosis or infectious diseases requiring systemic treatment;\n8. Known active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, multiple sclerosis, and glomerulonephritis (patients with vitiligo are not excluded);\n9. History of organ transplantation, autologous\u002Fallogeneic stem cell transplantation, or renal replacement therapy;\n10. HCV antibody-positive with HCV RNA levels above the lower limit of detection; HIV antibody-positive; syphilis antibody-positive;\n11. Currently pregnant or breastfeeding, or planning to become pregnant during the study;\n12. Participants deemed by the investigator to be unable or unwilling to comply with the requirements of the study protocol.","75 Years",{"count":57,"type":21},15,[59],"PHASE1","This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.",[27,62],"GPC3 Positive Hepatocellular Carcinoma",[64,65,66,67],"GPC3 CAR-T","Cell therapy","Immunotherapy","Hepatocellular Carcinoma","2026-05-12",{"date":70,"type":39},"2026-05-14",{"date":72,"type":39},"2026-03-27",{"date":74,"type":21},"2028-07-30",{"name":76,"class":77},"Guangzhou FineImmune Biotechnology Co., LTD.","INDUSTRY",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":78},"100604252","different-first-line-immunotherapy-for-advancer-hepatocellular-carcinoma-a-prospective-observational-study-on-efficacy-and-immune-microenvironment-100604252","NCT07147101","Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","A Prospective, Non-interventional Study of Different First-line Immunotherapy in Advanced Hepatocellular Carcinoma Patients: Efficacy and Immune Microenvironment Dynamics","HCC-IM-1","Inclusion Criteria:\n\n* Age ≥ 18 years at time of study entry.\n* Barcelona Clinic Liver Cancer stage C, or stage B not amenable to curative or locoregional therapies.\n* HCC confirmed by radiology, histology or cytology.\n* No prior systemic therapy for HCC.\n* At least one measurable site of disease as defined by RECIST1.1criteria with spiral CT scan or MRI.\n* Child-Pugh scores 5-7, performance status (PS) ≤ 2 (ECOG scale).\n* Adequate organ function:\n\n  * ANC ≥1.5 × 10⁹\u002FL, platelets ≥100 × 10⁹\u002FL, hemoglobin ≥9 g\u002FdL.\n  * Total bilirubin ≤1.5 × ULN, AST\u002FALT ≤3 × ULN (≤5 × ULN if liver metastases).\n  * Creatinine ≤1.5 × ULN or CrCl ≥60 mL\u002Fmin.\n* Willing to provide archival\u002Ffresh tumor tissue and peripheral blood samples.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Prior systemic therapy for HCC\n* Active autoimmune disease requiring immunosuppression.\n* Active infection requiring IV antibiotics.\n* HIV-positive or active HBV\u002FHCV infection (HBsAg+ with HBV DNA ≥2000 IU\u002FmL; HCV RNA+).\n* Symptomatic CNS metastases.\n* Pregnancy\u002Flactation.\n* Any condition compromising protocol compliance or data interpretation per investigator.",{"count":88,"type":21},150,"OBSERVATIONAL","To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.",[27],"2026-04-18",{"date":94,"type":39},"2026-04-21",{"date":96,"type":39},"2025-09-01",{"date":98,"type":21},"2028-09-01",{"name":100,"class":46},"Fudan University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100634526","phase-1-phase-2-study-of-wgi-0301-plus-lenvatinib-in-patients-with-advanced-hcc-100634526","NCT07540832","Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC","An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy","Inclusion Criteria:\n\n* 1\\. ≥18 years of age on the day of signing informed consent, male or female. 2. Voluntarily agree to provide signed informed consent and are willing and able to comply with all aspects of the protocol.\n\n  3\\. Histologically or cytologically confirmed diagnosis of HCC, or clinical diagnosis of HCC as per AASLD criteria.\n\n  4\\. BCLC Stage C or BCLC Stage B with bilobar involvement and infiltrative nature that is only suitable for systemic anti-tumor therapy, and not suitable for any curative surgeries, liver transplantation, or local therapy (BCLC Classification see Appendix 6, Section 14.6).\n\n  5\\. Stage 1 only: At least first-line standard treatment failure (disease progression confirmed by imaging) or intolerance with no restriction on the number of prior lines of systemic treatment.\n\n  6\\. Stage 2 only: Patients must have objective radiographic disease progression or intolerance after only one prior line of systemic immunotherapy treatment with an anti-PD-1\u002F PD-L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies (Prior locoregional therapy such as surgery, radiofrequency ablation or trans-arterial chemoembolization are also allowed but not counted as systemic therapy, provided that progression has been documented after these therapies, and ≥4 weeks have elapsed since the last therapy).\n\n  7\\. Eligible for treatment with Lenvatinib, as determined by investigators according to the Package Insert and clinical judgment.\n\n  8\\. ECOG PS of 0 or 1 within 7 days prior to the first dose of study intervention (ECOG PS see Appendix 3 in Section 14.3).\n\n  9\\. Patients must have at least one measurable lesion according to RECIST 1.1 as determined by the investigator, and that has not been the target of local or regional therapy including trans-arterial chemoembolization, intra-arterial chemotherapy, ethanol, or radiofrequency ablation; a new area of tumor progression within or adjacent to a previously treated lesion, if clearly measurable by a radiologist, is acceptable.\n\n  10\\. Life expectancy in the judgement of the Investigator \\> 12 weeks. 11. Recovery to ≤ Grade 1 (CTCAE V6.0) from toxicities related to any prior treatments unless the adverse events are clinically non-significant and\u002F or stable on supportive therapy, such as alopecia, Grade 2 peripheral neuropathy, and hypothyroidism stabilized on hormone replacement therapy.\n\n  12\\. Collection of an archived tissue sample will be requested (where available) or agree to undergo tumor tissue biopsy for biomarker testing; however, a subject will not be precluded from participating in the study if tissue sample is not available for collection or is otherwise insufficient for analysis.\n\n  13\\. Patients must have adequate organ function as defined below:\n  * Child-Pugh Liver Function Class A or Class B (score ≤ 7) (see Appendix 6 in Section 14.6)\n  * AST and ALT ≤ 3.0 × ULN, and total bilirubin ≤ 2 × ULN\n  * Serum albumin ≥ 2.8 g\u002F dL\n  * CrCL ≥ 50 ml\u002F min (Cockcroft-Gault formula: CrCL (mL\u002F min) = \\[140-age(year)\\] × body weight (Kg)\u002F \\[72 × Scr (mg\u002F dl)\\]{ × 0.85 for female subjects})\n  * Urine protein \\\u003C 2+ by dipstick analysis; if urine protein is ≥ 2+, a 24-hour urine protein quantification must be performed. Patients with 24-hour urine protein ≥ 1 g will be excluded.\n  * International normalized ratio (INR) ≤ 2.0 (except for warfarin therapy)\n  * Hemoglobin ≥ 8.5 g\u002F dL, absolute neutrophil count \\> 1000\u002F mm3, platelet count ≥ 60 000\u002F mm3 (no blood transfusion, blood products, cell growth factors, albumin or any other corrective therapeutic drugs within 14 days) 14. Participants with HBV or HCV infection will be allowed if they meet the following criteria:\n  * HBV-HCC: Resolved HBV infection (as evidenced by detectable HBV surface antibody, detectable HBV core antibody, undetectable HBV DNA, and undetectable HBV surface antigen) or chronic HBV infection (as evidenced by detectable HBV surface antigen or HBV DNA). Subjects with chronic HBV infection must have HBV DNA \\\u003C 500 IU\u002F mL and should be managed according to treatment guidelines. Those on antiviral therapy at screening should have been treated for \\>2 weeks before the first dose.\n  * HCV-HCC: Resolved HCV infection (as evidenced by undetectable HCV RNA), or stable HCV infection (such as normal LFTs or being asymptomatic). Patients with positive HCV RNA requiring direct antiviral agent treatment, or those with HBV and HCV co-infection are excluded.\n\n    15\\. WOCBP must have a negative serum pregnancy within 3 days prior to receiving the first dose of study medication and must use accepted highly effective methods of contraception from the time of signing the informed consent through 6 months after the last dose of study drug. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, or be surgically sterile, for the duration of study participation, and for 3 months after completion of study drug administration. See Appendix 1 for protocol-approved highly effective methods of contraceptive combinations.\n\nExclusion Criteria:\n\n* 1\\. Pregnant or breastfeeding patients or expecting to conceive or father children within the projected duration of the study.\n\n  2\\. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma. 3. Complete occlusion of the major portal vein or vena cava due to HCC (The major portal vein is defined as the part of portal vein between the union of the splenic and superior mesenteric veins and the first bifurcation into the left and right vein).\n\n  4\\. Major surgery within 4 weeks prior to the first dose of study intervention, or presence of any serious unhealed wounds, ulcers, or untreated fractures at screening.\n\n  5\\. Previous identified allergy or hypersensitivity to components of WGI-0301 similar drugs or liposomal drugs or related excipients.\n\n  6\\. Previous identified allergy or hypersensitivity to components of Lenvatinib or similar drugs.\n\n  7\\. Stage 2 only: Has received prior Lenvatinib therapy or treatment with any agents targeting the PI3K\u002FAKT pathway.\n\n  8\\. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.\n\n  9\\. Locoregional therapy to the liver within 4 weeks prior to the first dose, including but not limited to TACE, radiotherapy, radiofrequency ablation, microwave (except palliative radiotherapy for bone pain relief completed at least 2 weeks prior to the first dose).\n\n  10\\. Small molecule targeted therapy and traditional Chinese medicine with antitumor indications received within 2 weeks prior to the first dose, or chemotherapy, biological therapy, and other antitumor treatments received within 4 weeks prior to the first dose.\n\n  11\\. Clinically significant abnormalities of glucose metabolism (e.g., Patients with diabetes mellitus type1 or diabetes mellitus type 2 requiring treatment, or those with HbA1c ≥8.0%.\n\n  12\\. Clinically significant cardiovascular disease including:\n  * Uncontrolled chronic hypertension, defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥ 90 mmHg based on the average of ≥ 2 measurements; or a history of hypertensive crisis or hypertensive encephalopathy.\n  * Clinically significant hypotension as assessed by the investigator (e.g., systolic blood pressure \\\u003C 90 mmHg or mean arterial pressure \\\u003C 65 mmHg on two consecutive measurements at the Screening Visit).\n  * NYHA class III or IV Congestive heart failure, myocardial infarction or stroke, unstable angina pectoris, pericardial effusion (excluding trace pericardial effusion identified by echocardiography) or left ventricular ejection fraction \\\u003C 45% within 6 months prior to the first dose.\n  * Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, indeterminate cardiomyopathy).\n  * Bradycardia (known history of cardiovascular disease and either physical examination at rest or electrocardiogram indicating heart rate \\\u003C 50 bpm), or screening ECG indicating QTcF \\> 470 msec, 2 retests were required for the first abnormal QTcF, and 3 mean values were taken. Or there is severe arrhythmia requiring further treatment, including but not limited to ventricular fibrillation, atrial fibrillation, sustained ventricular tachycardia, second-degree or third-degree atrioventricular block, torsades de pointes, etc.\n\n    13\\. Clinically significant gastrointestinal disorders including:\n  * Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and\u002For absorption of the tested products.\n  * Gastrointestinal perforation and\u002F or fistula intra-abdominal abscess or intestinal obstruction within 6 months prior to the first dose.\n  * Clinically significant gastric bleeding within 6 months prior to the first dose (patients may be enrolled if esophageal and gastric varices are present on imaging, but no bleeding event or inpatient medical intervention occurs within 6 months prior to the first dose).\n\n    14\\. Clinically significant bleeding risks including:\n  * Known hereditary or acquired bleeding or thrombotic tendencies (e.g., hereditary hemorrhagic telangiectasia or von Willebrand disease)\n  * Bleeding symptoms such as hemoptysis (\\> half teaspoon bright red blood) and gastrointestinal bleeding within 3 months prior to screening\n  * Thrombolytic agents within 10 days prior to the first dose\n  * Receiving anticoagulant therapy (e.g., anticoagulants, antiplatelets), and subject 's INR and APTT are not within expected therapeutic range of anticoagulant (except sodium heparin for maintenance of central venous catheter patency) 15. History of solid organ transplant. 16. Known HIV or AIDS related illness or is receiving systemic steroid therapy (prednisone \\\u003C10 mg\u002Fday or equivalent doses of other corticosteroids are acceptable) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n\n    17\\. Known active or uncontrolled infection that could interfere with the study (such as requiring intravenous antibiotics, antiviral or antifungal medications).\n\n    18\\. Uncontrolled ascites or pleural effusion requiring repeated drainage (Investigator 's judgment).\n\n    19\\. Past or current history of neoplasm other than HCC, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 3 years.\n\n    20\\. Known CNS or leptomeningeal metastasis that is either symptomatic or untreated (except for asymptomatic cases not requiring treatment).\n\n    21\\. History of drug abuse or addiction at the present stage. 22. Subject has any other conditions or reason that, in the opinion of the Investigator, interferes with the ability of the subject to participate in the trial, places the subject at undue risk or complicates the interpretation of data",{"count":109,"type":21},80,[59,24],"This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.",[27],"NOT_YET_RECRUITING","2026-04-14",{"date":116,"type":39},"2026-04-20",{"date":118,"type":21},"2026-09",{"date":120,"type":21},"2028-10",{"name":122,"class":77},"Zhejiang Haichang Biotech Co., Ltd.",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":78},"100631403","phase-1-dual-target-gpc3b7-h3-car-nk-cells-for-advanced-hcc-100631403","NCT07500220","Dual-Target GPC3\u002FB7-H3 CAR-NK Cells for Advanced HCC","A Phase 1\u002F2, Open-Label, Dose-Escalation and Dose-Expansion Study of Allogeneic Dual-Target GPC3\u002FB7-H3 (CD276) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Relapsed\u002FRefractory, or Metastatic Hepatocellular Carcinoma","DUET-HCC","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Histologically or cytologically confirmed HCC, or radiologically diagnosed HCC with mandatory tissue confirmation of target expression before enrollment.\n* Unresectable, locally advanced, or metastatic HCC not amenable to curative surgery, transplant, or further locoregional therapy; BCLC stage C, or stage B that is not suitable for or has progressed after locoregional therapy.\n* Disease progression on, intolerance to, or ineligibility for at least 1 prior standard systemic regimen.\n* Central pathology showing GPC3 positivity in \\>=25% of viable tumor cells by IHC and B7-H3 positivity in \\>=10% of tumor cells and\u002For tumor-associated stromal\u002Fvascular cells by IHC.\n* At least 1 measurable lesion by RECIST 1.1; intrahepatic lesions must be assessable by contrast-enhanced triphasic CT or MRI.\n* ECOG performance status 0 to 1.\n* Child-Pugh class A or stable Child-Pugh B7 without uncontrolled ascites or recent encephalopathy.\n* Estimated life expectancy \\>=12 weeks.\n* Adequate organ function: WBC \\>=2.5 x 10\\^9\u002FL; platelets \\>=60 x 10\\^9\u002FL; hemoglobin \\>=9 g\u002FdL; serum albumin \\>=30 g\u002FL; creatinine clearance \\>=40 mL\u002Fmin; AST\u002FALT \\\u003C=5 x ULN; total bilirubin \\\u003C=2.5 x ULN; INR\u002Fprothrombin time within protocol-defined range.\n* If HBsAg positive or anti-HBc positive, HBV DNA must be \\\u003C200 IU\u002FmL and the participant must be on appropriate antiviral therapy before lymphodepletion. Controlled HCV is allowed if per protocol.\n* Negative serum pregnancy test for participants of childbearing potential and agreement to effective contraception.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (for example prior CAR-T, CAR-NK, or TCR-engineered therapy) within the protocol-defined washout period or with unresolved clinically significant toxicity.\n* Active, uncontrolled infection, including uncontrolled bacterial, viral, or fungal infection; uncontrolled HIV; active HBV or HCV with uncontrolled viral load; or active tuberculosis.\n* Known active CNS metastases or leptomeningeal disease requiring escalating steroids or urgent local intervention.\n* Liver transplant or other solid-organ transplant history, or current requirement for chronic immunosuppression.\n* Clinically significant ascites requiring frequent drainage, grade \\>=2 hepatic encephalopathy within 4 weeks, or recent clinically significant variceal\u002FGI bleeding.\n* Extensive liver replacement by tumor (for example \\>=70%) or complete major portal vein\u002Fhepatic venous obstruction judged to create excessive treatment risk.\n* Major surgery, locoregional therapy, radiotherapy, or systemic anticancer therapy too close to lymphodepletion per protocol-defined washout period.\n* Active autoimmune disease requiring systemic immunosuppressive therapy, or chronic systemic corticosteroids above protocol threshold.\n* Clinically significant cardiovascular disease (recent myocardial infarction, unstable arrhythmia, uncontrolled heart failure), uncontrolled pulmonary disease, or other serious comorbidity that materially increases study risk.\n* Pregnant or breastfeeding.\n* Any other active malignancy that is progressing or requires current systemic treatment.\n* Any medical or psychiatric condition that, in the investigator's judgment, would compromise safety, protocol compliance, or interpretation of results.",{"count":132,"type":21},30,[59,24],"open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.",[27,136],"Metastatic Liver Cancer",[138,139,140,141,142,143,144,145,146,147,148,149,150,151],"HCC","liver cancer","epatocellular carcinoma","GPC3","glypican-3","B7-H3","CD276","CAR-NK","dual-target","NK cell therapy","adoptive cell therapy","cell therapy","immunotherapy","allogeneic","2026-03-24",{"date":154,"type":39},"2026-03-30",{"date":156,"type":39},"2026-03-02",{"date":158,"type":21},"2028-03-17",{"name":160,"class":77},"Beijing Biotech",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100539872","phase-2-phase-2-study-of-wgi-0301-for-advanced-hcc-100539872","NCT06309485","Phase 2 Study of WGI-0301 for Advanced HCC","An Open-Label Phase 1\u002F2 Study of WGI-0301 Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy","Inclusion Criteria:\n\n1. ≥18 years of age on the day of signing informed consent, male or female.\n2. Voluntarily agree to provide signed informed consent and are willing and able to comply with all aspects of the protocol.\n3. Histologically or cytologically confirmed diagnosis of HCC, or clinical diagnosis of HCC as per 2018 AASLD criteria.\n4. BCLC Stage C or BCLC Stage B with bilobar involvement and infiltrative nature that is only suitable for systemic anti-tumor therapy, and not suitable for any curative surgeries, liver transplantation, or local therapy (BCLC Classification see Appendix 6, Section 14.6).\n5. Stage 1 only: At least first-line standard treatment failure (disease progression confirmed by imaging) with no available standard treatment options, or unsuitability for standard treatment, or intolerance to standard treatment.\n6. Stage 2 only: At least first-line standard treatment failure (disease progression confirmed by imaging) or intolerance.\n7. Stage 3 only: Patients must have objective radiographic disease progression or intolerance (Intolerance is defined as currently discontinued after ≥28 days of treatment due to toxicity) after only one prior line of systemic immunotherapy treatment with an anti-PD-1\u002F PD-L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies (Prior locoregional therapy such as surgery, radiofrequency ablation or trans-arterial chemoembolization are also allowed but not counted as systemic therapy, provided that progression has been documented after these therapies, and ≥4 weeks have elapsed since the last therapy).\n8. Stage 2 and Stage 3: Eligible for treatment with Sorafenib as determined by investigators according to the Package Insert and clinical judgment.\n9. ECOG PS of 0 or 1 within 7 days prior to the first dose of study intervention.\n10. Patients must have at least one measurable lesion according to RECIST 1.1 as determined by the investigator, and that has not been the target of local or regional therapy including trans-arterial chemoembolization, intra-arterial chemotherapy, ethanol, or radiofrequency ablation; a new area of tumor progression within or adjacent to a previously treated lesion, if clearly measurable by a radiologist, is acceptable.\n11. Life expectancy in the judgement of the Investigator \\> 12 weeks.\n12. Recovery to ≤Grade 1 (CTCAE V5.0) from toxicities related to any prior treatments unless the adverse events are clinically non-significant and\u002F or stable on supportive therapy, such as alopecia, Grade 2 peripheral neuropathy, and hypothyroidism stabilized on hormone replacement therapy.\n13. Stage 2 and Stage 3:Collection of an archived tissue sample will be requested (where available) or agree to undergo tumor tissue biopsy for biomarker testing; however, a subject will not be precluded from participating in the study if tissue sample is not available for collection or is otherwise insufficient for analysis.\n14. Patients must have adequate organ function as defined below:\n\n    * Child-Pugh Liver Function Class A or Class B (score ≤ 7) (see Appendix 7 in Section 14.7)\n    * AST and ALT ≤ 3.0 × ULN and total bilirubin ≤ 2 × ULN\n    * Serum albumin ≥ 2.8 g\u002F dL\n    * CrCL ≥ 40 ml\u002F min (Cockcroft-Gault formula: CrCL (mL\u002F min) = \\[140-age(year)\\] × body weight (Kg)\u002F \\[72 × Scr (mg\u002F dl)\\]{ × 0.85 for female subjects})\n    * INR ≤ 2.0 (except for warfarin therapy)\n    * Hemoglobin ≥ 8.5 g\u002F dL, absolute neutrophil count \\> 1000\u002F mm3, platelet count ≥ 60 000\u002F mm3(no blood transfusion, blood products, cell growth factors, albumin or any other corrective therapeutic drugs within 14 days)\n15. Participants with HBV or HCV infection will be allowed if they meet the following criteria:\n\n    * HBV-HCC: Resolved HBV infection (as evidenced by detectable HBV surface antibody, detectable HBV core antibody, undetectable HBV DNA, and undetectable HBV surface antigen) or chronic HBV infection (as evidenced by detectable HBV surface antigen or HBV DNA). Subjects with chronic HBV infection must have HBV DNA \\\u003C 500 IU\u002F mL and must should be managed according to treatment guidelines. Those on antiviral therapy at screening should have been treated for \\>2 weeks before the first dose.\n    * HCV-HCC: Resolved HCV infection (as evidenced by detectable HCV RNA or antibody), or stable HCV infection (such as normal LFTs or being asymptomatic). Patients with positive HCV RNA requiring direct antiviral agent treatment, or those with HBV and HCV co-infection are excluded.\n16. WOCBP must have a negative serum pregnancy within 3 days prior to receiving the first dose of study medication and must use accepted highly effective methods of contraception from the time of signing the informed consent through 6 months after the last dose of study drug. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, or be surgically sterile, for the duration of study participation, and for 3 months after completion of study drug administration. See Appendix 1 for protocol-approved highly effective methods of contraceptive combinations.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients or expecting to conceive or father children within the projected duration of the study.\n2. Stage 2 and Stage 3: Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.\n3. Complete occlusion of the major portal vein or vena cava due to HCC (The major portal vein is defined as the part of portal vein between the union of the splenic and superior mesenteric veins and the first bifurcation into the left and right vein).\n4. Major surgery within 4 weeks prior to the first dose of study intervention.\n5. Previous identified allergy or hypersensitivity to components of WGI-0301 similar drugs or liposomal drugs or related excipients.\n6. Stage 2 and Stage 3: Previous identified allergy or hypersensitivity to components of Sorafenib or similar drugs.\n7. Stage 3 only: Received prior Sorafenib therapy or any agents targeting AKT-PI3K pathway.\n8. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention (except for observational clinical trials).\n9. Locoregional therapy to liver within 4 weeks prior to the first dose, including but not limited to TACE, radiotherapy, radiofrequency ablation, microwave (except palliative radiotherapy for bone pain relief completed at least 2 weeks prior to the first dose).\n10. Small molecule targeted therapy and traditional Chinese medicine with antitumor indications received within 2 weeks prior to the first dose, or chemotherapy, biological therapy, and other antitumor treatments received within 4 weeks prior to the first dose.\n11. Stage 2 and Stage 3：Patients on concomitant use of strong CYP3A4 inducers (see Appendix 3 in Section 14.3) within 12 days prior to the first dose of study intervention.\n12. Clinically significant abnormalities of glucose metabolism (e.g., Patients with diabetes mellitus type1 or diabetes mellitus type 2 requiring treatment, or those with HbA1c ≥8.0%.\n13. Clinically significant cardiovascular disease including:\n\n    * Uncontrolled chronic hypertension defined as systolic \\> 150 mmHg or diastolic \\> 90 mmHg on more than one measurement despite optimal therapy (initiation or adjustment of BP medication prior to study entry is allowed provided that the average of 3 BP readings prior to enrollment is \\\u003C 150\u002F 90 mmHg).\n    * Hypotension as indicated by systolic blood pressure \\\u003C 90 mmHg or mean arterial pressure \\\u003C 65 mmHg on 2 consecutive measurements at the Screening Visit.\n    * NYHA class III or IV Congestive heart failure, myocardial infarction or stroke, unstable angina pectoris, pericardial effusion (excluding trace pericardial effusion identified by echocardiography), or left ventricular ejection fraction \\\u003C 45% within 6 months prior to the first dose.\n    * Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, indeterminate cardiomyopathy).\n    * Bradycardia (known history of cardiovascular disease and either physical examination at rest or electrocardiogram indicating heart rate \\\u003C 50 bpm), or screening ECG indicating QTcF \\> 470 msec, 2 retests were required for the first abnormal QTcF , and 3 mean values were taken. Or there is severe arrhythmia requiring further treatment, including but not limited to ventricular fibrillation, atrial fibrillation, sustained ventricular tachycardia, second-degree or third-degree atrioventricular block, torsades de pointes, etc.\n14. Stage 2 and Stage 3: Clinically significant gastrointestinal disorders including:\n\n    * Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and\u002F or absorption of the tested products\n    * Gastrointestinal perforation and\u002F or fistula intra-abdominal abscess or intestinal obstruction within 6 months prior to the first dose\n    * Clinically significant gastric bleeding within 6 months prior to the first dose (patients may be enrolled if esophageal and gastric varices are present on imaging, but no bleeding event or inpatient medical intervention occurs within 6 months prior to the first dose)\n15. Clinically significant bleeding risks including:\n\n    * Known hereditary or acquired bleeding or thrombotic tendencies (e.g., hereditary hemorrhagic telangiectasia or von Willebrand disease)\n    * Bleeding symptoms such as hemoptysis (\\> 1\u002F 2 teaspoon bright red blood) and gastrointestinal bleeding within 3 months prior to screening\n    * Thrombolytic agents within 10 days prior to the first dose\n    * Receiving anticoagulant therapy (e.g., anticoagulants, antiplatelets), and subject 's INR and APTT are not within expected therapeutic range of anticoagulant (except sodium heparin for maintenance of central venous catheter patency)\n16. History of solid organ transplant.\n17. Known HIV or AIDS related illness or is receiving systemic steroid therapy (physiological doses of hormones, such as prednisone \\\u003C10 mg\u002Fday or equivalent doses of similar corticosteroids are acceptable) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n18. Known active or uncontrolled infection that could interfere with the study (such as requiring intravenous antibiotics, antiviral or antifungal medications).\n19. Uncontrolled ascites or pleural effusion requiring repeated drainage (Investigator 's judgment).\n20. Past or current history of neoplasm other than HCC, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 3 years.\n21. Known CNS or brain metastasis that is either symptomatic or untreated (except for asymptomatic cases not requiring treatment).\n22. History of drug abuse or addiction at the present stage.\n23. Subject has any other conditions or reason that, in the opinion of the Investigator, interferes with the ability of the subject to participate in the trial, places the subject at undue risk or complicates the interpretation of data.",{"count":169,"type":21},60,[24],"The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 \u002F PD-L1 immune checkpoint inhibitors.",[27],"2026-03-16",{"date":175,"type":39},"2026-03-19",{"date":177,"type":39},"2024-07-31",{"date":179,"type":21},"2027-03",{"name":122,"class":77},4,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100595957","a-study-to-evaluate-cg-102-12c-in-glypican-3-gpc3-positive-advanced-hepatocellular-carcinoma-hcc-100595957","NCT07039201","A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)","An Exploratory Clinical Study on the Safety and Efficacy of Autologous Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CG-102-12C) in the Treament of Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* 1\\. The study participant has fully understood the potential risks and benefits of participating in this study and has signed the informed consent form.\n* 2\\. Aged 18-75 years (inclusive of 18 and 75 years old).\n* 3\\. Patients with advanced hepatocellular carcinoma (HCC) confirmed by histopathological or cytological examination to be GPC3-positive (advanced HCC is defined as Barcelona Clinic Liver Cancer (BCLC) stage C or stage B that is unsuitable for or has progressed after local treatment, including ablation therapy, interventional therapy, and radiotherapy). Patients must have previously received systemic standard treatment and experienced treatment failure or intolerance (systemic treatments include, but are not limited to, chemotherapy and molecular targeted therapy). Treatment failure is defined as disease progression during or after the most recent treatment.\n* 4\\. Immunohistochemical analysis of tumor tissue samples must show GPC3 positivity (defined as \\>25% of pathological specimens with IHC-detected GPC3-positive cells and staining intensity ≥1+). Preferably ,target lesion specimens will be used, including freshly obtained tumor pathology samples or archived tumor pathology samples deemed acceptable by the investigator.\n* 5\\. Child-Pugh score ≤7.\n* 6\\. At least one evaluable tumor lesion as assessed by RECIST 1.1.\n* 7\\. ECOG performance status score of 0-2.\n* 8\\. Expected survival ≥3 months.\n* 9\\. Hematological parameters must meet the following criteria:Absolute neutrophil count (ANC) ≥1×10\\^9\u002FL;Absolute lymphocyte count (ALC) ≥0.5×10\\^9\u002FL;Platelets ≥50×10\\^9\u002FL;Hemoglobin ≥60 g\u002FL or hematocrit \\>0.24.(No treatment with hematopoietic growth factors or blood transfusion within 3 days prior to laboratory tests).\n* 10.Blood biochemistry must meet the following criteria:Total bilirubin (TBIL) ≤2.5 times the upper limit of normal (ULN);AST and ALT ≤5.0 times ULN;Serum albumin ≥28 g\u002FL;Serum creatinine ≤1.5 times ULN;Creatinine clearance \\>50 mL\u002Fmin (calculated using the Cockcroft-Gault formula).\n* 11.Coagulation parameters must meet the following criteria:INR \\\u003C1.5 times ULN;APTT \\\u003C1.5 times ULN;PT prolongation ≤4 seconds.\n* 12.If the patient is HBsAg positive or HBcAb positive, it is required that HBV-DNA ≤2000 IU\u002FmL;\n* 13.At screening, during apheresis, and within 3 days prior to preconditioning, female study participants of childbearing potential must have a negative blood pregnancy test; during the study period and for at least 1 year after completion of the study treatment, study participants of childbearing potential and their partners must use effective contraception.\n\nExclusion Criteria:\n\n* 1\\. History of a second primary malignancy is permitted, unless the patient has undergone potentially curative treatment and has been free of the disease for 5 years.\n\nNote: This time requirement (i.e., within 5 years) does not apply to patients with adequately treated carcinoma in situ of the cervix, localized squamous cell carcinoma of the skin, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, or urothelial carcinoma \\\u003CT1. Patients with prostate cancer under active surveillance are also eligible, or patients deemed eligible by the investigator after thorough evaluation.\n\n* 2\\. Prior treatment with CAR-T or TCR-T cell therapy targeting any antigen or therapeutic cancer vaccines; or prior treatment with any therapy targeting GPC3.\n* 3\\. Prior to apheresis, the patient has received the following antitumor therapies: Cytotoxic therapy within 14 days; Small molecule targeted therapy, epigenetic therapy, or experimental drug therapy within 14 days or at least 5 half-lives (whichever is longer), or treatment with invasive experimental medical devices; Monoclonal antibody therapy within 21 days; Immunomodulatory therapy within 7 days; Radiotherapy within 14 days.\n* 4\\. Toxicities from prior antitumor therapies have not recovered to ≤ Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0), except for alopecia, Grade 2 peripheral neuropathy, and hypothyroidism controlled by hormone replacement therapy.\n* 5\\. History of organ transplantation or currently awaiting organ transplantation (including liver transplantation).\n* 6\\. Brain metastases with central nervous system symptoms or other clinically significant central nervous system diseases.\n* 7\\. History of hepatic encephalopathy or current presence of hepatic encephalopathy.\n* 8\\. Ascites requiring therapeutic intervention (excluding any ascites detected by imaging that does not require clinical intervention).\n* 9\\. HCC tumor volume occupying ≥50% of the normal liver volume based on imaging, or presence of tumor thrombus in the main portal vein or inferior vena cava, or patients deemed ineligible by the investigator.\n* 10.Women who are pregnant or breastfeeding.\n* 11.Positive screening for hepatitis C virus antibody (HCV-Ab) or human immunodeficiency virus antibody (HIV-Ab); active syphilis. (Patients with positive HCV antibody but HCV-RNA below the detection limit of the research center are allowed to enroll).\n* 12.Presence of severe underlying diseases, such as: Evidence of severe active viral, bacterial, or uncontrolled systemic fungal infections; Active or unstable autoimmune diseases or a history of autoimmune diseases within the past 3 years with potential for recurrence (including, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; patients with vitiligo; childhood asthma that has completely resolved and requires no intervention in adulthood may be included; asthma requiring medical intervention with bronchodilators is excluded); Uncontrolled diabetes; Severe congestive heart failure classified as New York Heart Association (NYHA) Class III or above, or patients with an ejection fraction \\\u003C50%; history of myocardial infarction or unstable angina within 6 months prior to treatment; Hypertension that cannot be controlled to the following range (systolic blood pressure \\\u003C160 mmHg, diastolic blood pressure \\\u003C100 mmHg) despite treatment with two antihypertensive medications; Clinically significant ventricular arrhythmias, or a history of unexplained syncope not due to vasovagal causes or dehydration; patients with constrictive pericarditis, significant pericardial effusion, cardiomyopathy, low voltage on limb leads of electrocardiogram, or other cardiac conditions deemed unsuitable by the investigator; Patients with clinically significant dementia, altered mental status, or a history of poorly controlled psychiatric disorders.\n* 13.History of stroke or seizure within 6 months prior to signing the ICF.\n* 14.Significant bleeding tendency, such as active gastrointestinal bleeding or coagulation disorders.\n* 15.Chronic diseases requiring systemic corticosteroids or other immunosuppressive therapy, or treatment with systemic corticosteroids (≥70 mg prednisone or equivalent doses of other corticosteroids) or other immunosuppressive agents within 7 days prior to apheresis, except for the following: use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of corticosteroids for prophylactic purposes (e.g., prevention of contrast agent allergy).\n* 16.Administration of live attenuated vaccines within 4 weeks prior to apheresis.\n* 17.Major surgery within 2 weeks prior to apheresis, or planned surgery during the study period (Note: Study participants scheduled for local anesthesia surgery may participate in this study).\n* 18.History of severe allergic reactions, or hypersensitivity to any drugs or related excipients specified in the protocol, as determined by the investigator to be unsuitable for enrollment.\n* 19.Any condition that, in the opinion of the investigator, makes the study participant unsuitable for participation in this study.",{"count":190,"type":21},12,[192],"NA","This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.",[27],[196,197,141],"Advanced Hepatocellular Carcinoma","Chimeric antigen receptor T Cell","2026-01-19",{"date":200,"type":39},"2026-01-22",{"date":202,"type":39},"2025-06-28",{"date":204,"type":21},"2027-07-31",{"name":206,"class":46},"Zhejiang University",2,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":207},"100579752","phase-2-a-study-comparing-immunotherapy-alone-versus-immunotherapy-combined-with-radiotherapy-in-patients-with-hepatocellular-carcinoma-hcc-with-vascular-invasion-100579752","NCT06828380","A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion","A Phase II Study of Immunotherapy With or Without Particle Beam Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma Who Have Vascular Invasion: IOPT Study","IOPT","Inclusion Criteria:\n\n1. Signed informed consent form\n2. Age \\>= 19 at the time of signing Informed consent form\n3. Histological or clinical diagnosis of HCC based on the guidelines of the Korean Liver Cancer Association -National Cancer Center\n4. Unresectable and\u002For locally advanced or metastatic disease showing major vascular invasion\n\n   a. Presence of major vascular invasion on dynamic CT or dynamic MRI (1+2)\n   * an intraluminal filling defect adjacent to the primary tumor in portal vein, hepatic vein, and\u002For inferior vena cava\n   * an enhancement of the filling defect on arterial phase and a washout on portal\u002Fdelayed phases\n5. Having at least one measurable target lesion (per RECIST v1.1)\n\n   a. Participants who received prior locoregional therapy (e.g., radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization, transarterial embolization, radiation therapy etc.) are eligible provided that other target lesion(s) have not been previously treated with locoregional therapy or the target lesion(s) within the field of locoregional therapy have subsequently progressed in accordance with RECIST v1.1.\n6. Child-Pugh class A\n7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 28 days prior to screening:\n\n   1. Hemoglobin ≥ 8.0 g\u002FdL\n   2. Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   3. Platelet count ≥ 50,000\u002FμL\n   4. Total bilirubin \\\u003C 3.0 mg\u002FdL\n   5. Serum albumin ≥ 2.8 g\u002FdL\n   6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × the upper limit of normal (ULN)\n   7. Prothrombin time in INR ≤ 1.8 × ULN\n   8. Serum creatinine ≤ 2.0 × ULN or calculated creatinine clearance ≥ 40 mL\u002Fmin (using the Cockcroft-Gault equation)\n9. Documented virology status of hepatitis, as confirmed by screening tests for HBV and HCV\n\n   a. Participants with HBV or HCV infection must be treated with antiviral therapy as per institutional practice.\n10. Female participants of childbearing potential must agree to either remain abstinent or use effective contraception (with a failure rate of \\\u003C1% per year) since signing of the informed consent form until at least 6 months after the last study drug administration.\n11. Male participants must agree to remain abstinent or use a condom and refrain from donating sperm since signing of the informed consent form until at least 6 months after the last study drug administration.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma or sarcomatoid carcinoma\n2. Receipt of 2 or more prior systemic therapy for advanced HCC. Additional prior systemic therapies used as adjuvant or local therapy are allowed.\n3. Receipt of other first-line systemic therapy than immune checkpoint inhibitor-based regimen\n4. Receipt of prior radiation therapy to liver\n\n   a. Participants are excluded if the potential radiation field overlaps with a previously irradiated area.\n5. Receipt of locoregional therapy for HCC within 28 days prior to initiation of study treatment or non-recovery from complications due to the procedure (radiofrequency ablation, microwave ablation, cryoablation, trans-arterial embolization including chemo- and radio-embolization, or radiation therapy).\n\n   a. A 7-day washout is permitted for palliative radiation to bone lesions\n6. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, or multiple sclerosis with following exceptions:\n\n   1. Patients with hypothyroidism stable on hormone replacement\n   2. Controlled type 1 diabetes mellitus and on an insulin regimen\n   3. Any chronic skin condition that does not require systemic therapy\n7. Prior allogeneic stem cell or solid organ transplantation\n8. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to initiation of study treatment\n9. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n10. Having active brain metastasis or leptomeningeal metastasis\n11. Moderate to severe or intractable ascites\n12. Presence of hepatic encephalopathy\n13. History of malignancy other than HCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%)\n14. Uncontrolled severe medical comorbidities, including significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to the initiation of study treatment, unstable arrhythmia, or unstable angina or any significant medical illness or abnormal laboratory findings that, in the investigator's judgement, would increase the risk to the participant associated with study participation\n15. Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 6 months after the last study drug administration\n16. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements","19 Years",{"count":218,"type":21},128,[24],"In the present study, we aim to investigate the efficacy and safety of concurrent therapy of Immunotherapy based combination therapy and Radiotherapy in patients with advanced HCC showing macrovascular invasion.",[27],"2025-12-24",{"date":224,"type":39},"2025-12-26",{"date":226,"type":39},"2025-04-15",{"date":228,"type":21},"2028-08-06",{"name":230,"class":231},"National Cancer Center, Korea","OTHER_GOV",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":239,"targetDuration":241,"studyType":89,"phases":4,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":207},"100617626","use-of-immune-checkpoint-inhibitors-in-patients-with-advanced-hepatocellular-carcinoma--efficacy-and-outcomes-100617626","NCT07321067","Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","ICIs","Inclusion Criteria:\n\n* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC\n* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).\n* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .\n\nExclusion Criteria:\n\n* Child-Pugh C liver function.\n* Prior liver transplantation.\n* patients with concurrent malignancies other than HCC.\n* Active autoimmune disease requiring systemic immunosuppression.",{"count":240,"type":21},75,"12 Months","the Objectives of this study are:\n\n• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.\n\nthe main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.",[27],[245,246],"advanced hepatocellular carcinoma","immune checkpoint inhibitors","2025-12-21",{"date":249,"type":39},"2026-01-06",{"date":251,"type":21},"2026-01-01",{"date":253,"type":21},"2027-11-01",{"name":255,"class":46},"Ahmed Karam Helmy",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100614662","phase-1-safety-and-efficacy-of-paclitaxel-liposome-arterial-infusion-combined-with-systemic-therapy-for-second-line-treatment-of-advanced-liver-cancer-100614662","NCT07282509","Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","A Phase Ib\u002FII Clinical Trial to Evaluate the Safety and Efficacy of Transcatheter Arterial Infusion of Paclitaxel Cationic Liposome Combined With Systemic Therapy in Participants With Advanced Hepatocellular Carcinoma for Second-line Treatment","Inclusion Criteria:\n\n* 1.Aged 18 to 75 years (inclusive), regardless of gender;\n* 2.Diagnosed with hepatocellular carcinoma (HCC) by histopathology, cytology, or imaging;\n* 3.HCC classified as B\u002FC stage per BCLC (Barcelona Clinic Liver Cancer) staging system, or IIb\u002FIIIa\u002FIIIb stage as defined in Clinical Practice Guidelines for Primary Liver Cancer (2024 Edition) (organized by the Guidelines Committee of the Chinese Society of Clinical Oncology, 2024);\n* 4.Child-Pugh liver function class ≤ 7 points within 7 days prior to the first dose administration;\n* 5.Progressive disease after prior first-line systemic antineoplastic therapy containing PD-1\u002FPD-L1 monoclonal antibody;\n* 6.At least one measurable lesion at the hepatic arterial infusion site per RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1 (lesion longest diameter ≥ 1 cm; lesions that have not received prior local therapy, or lesions that progressed again after local therapy);\n* 7.ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) score: 0-1.\n* 8.Controlled hypertension, with blood pressure ≤ 150\u002F90 mmHg and no changes to the antihypertensive regimen within one week prior to screening;\n* 9.Estimated survival time of more than 3 months;\n* 10.Before randomization, major organ\u002Fsystem functions are basically normal, meeting the criteria as assessed by laboratory tests.\n* 11.Eligible individuals of childbearing potential (both males and females) must agree to use reliable contraceptive methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the trial and for at least 6 months after the last dose; female individuals of childbearing age must have a negative serum pregnancy test within 7 days before enrollment;\n* 12.Participants must be informed about the study prior to the trial and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n* 1.Pathologically confirmed fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, cholangiocellular carcinoma, or combined hepatocellular-cholangiocarcinoma;\n* 2.History of liver surgery and\u002For local treatment for HCC within 4 weeks prior to the first dose;\n* 3.Previous antineoplastic treatment with lenvatinib;\n* 4.Use of traditional Chinese medicine (TCM) preparations with indicated efficacy for anti-HCC within 14 days prior to the first dose; having received immune checkpoint inhibitors within 28 days prior to the first dose.\n* 5.Active brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression;\n* 6.Adverse reactions from previous antineoplastic treatment that have not resolved to ≤ Grade 1 per NCI-CTCAE Version 5.0 (except for toxicities such as alopecia that are deemed to pose no safety risks by the investigator);\n* 7.Contraindications to transcatheter arterial infusion interventional surgery; known contraindications or severe allergic reactions to any component of lenvatinib, PD-1\u002FPD-L1 monoclonal antibody, paclitaxel, or cationic liposomes;\n* 8.Malabsorption syndrome or inability to take oral medications due to other reasons;\n* 9.Need for administration of strong inducers or strong inhibitors of CYP2C8 and CYP3A4 within 2 weeks prior to the first study treatment or during the treatment period;\n* 10.Active infection within 2 weeks prior to the first dose; presence of peripheral neuropathy of Grade II or higher (per NCI-CTCAE Version 5.0);\n* 11.History of autoimmune disease, immunodeficiency, other acquired or congenital immunodeficiency diseases, or current use of immunosuppressants;\n* 12.Untreated active hepatitis B.\n* 13.Participants positive for anti-hepatitis C virus antibody (HCV-Ab) with HCV-RNA level above the lower limit of the central laboratory's detection range;\n* 14.Participants with active syphilis;\n* 15.A history of past or current hepatic encephalopathy;\n* 16.Presence of ascites detectable on physical examination, ascites causing clinical symptoms, or ascites requiring special management during screening. Uncontrolled pleural effusion or pericardial effusion during screening;\n* 17.Active gastrointestinal bleeding or a documented history of gastrointestinal bleeding within 6 months before the first dose; history of gastrointestinal perforation and\u002For fistula, or history of gastrointestinal obstruction within 6 months before the first dose;\n* 18.History of major surgery within 4 weeks before the first dose (procedures such as central venous catheterization, needle biopsy, and feeding tube placement are not considered major surgery);\n* 19.History of solid organ or hematopoietic stem cell transplantation;\n* 20.Past or current non-infectious pneumonia\u002Finterstitial lung disease requiring systemic glucocorticoid treatment;\n* 21.Cardiac dysfunction, including:\n\n  1. Diagnosis of long QT syndrome, or QTcF (corrected QT interval using Fridericia's formula) ≥ 450 ms in males and ≥ 470 ms in females during screening (only one ECG recheck is permitted during screening, with the result of the last ECG in the screening period taken as final);\n  2. High-grade atrioventricular block;\n  3. Malignant arrhythmia poorly controlled by medication;\n  4. History of chronic heart failure with NYHA (New York Heart Association) functional class ≥ 3;\n  5. Severe valvular heart regurgitation or stenosis requiring treatment;\n  6. Acute coronary syndrome or severe myocardial disease (including primary cardiomyopathy and other severe myocardial diseases assessed by the investigator) within 6 months prior to screening; severe pericardial disease (including acute pericarditis, constrictive pericarditis and other severe pericardial diseases assessed by the investigator) within 6 months prior to screening;\n  7. Left ventricular ejection fraction (LVEF) \\\u003C 50% as indicated by echocardiography;\n* 22.History of severe neurological or psychiatric disorders (including epilepsy or dementia) that affect trial compliance;\n* 23.Limb vascular thrombosis with potential severe consequences detected by ultrasound during screening; or history of thromboembolic events within 12 months prior to enrollment;\n* 24.Participants with severe bleeding tendency, or history of major bleeding events within the past 6 months (e.g., previous intracranial hemorrhage, gastrointestinal bleeding, or purpura);\n* 25.Urinary protein ≥ 1 g\u002F24 h. Participants with proteinuria \\> 1+ on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria;\n* 26.Other conditions deemed by the investigator to potentially increase participant risk or interfere with trial results.",{"count":264,"type":21},116,[59,24],"This trial is an open-label, dose-escalation, and randomized controlled Phase Ib\u002FII clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.",[27],"2025-12-01",{"date":270,"type":39},"2025-12-15",{"date":272,"type":21},"2025-12-23",{"date":274,"type":21},"2029-02-03",{"name":276,"class":77},"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":78},"100585440","phase-1-a-clinical-study-of-multi-target-hi-tcr-t-cells-in-the-treatment-of-advanced-hepatocellular-carcinoma-100585440","NCT06902389","A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma","A Prospective Study on Super Hi-TCR-T Cells Targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP for the Treatment of Refractory\u002FRelapsed Advanced Liver Cancer and Other Solid Tumors","Inclusion criteria:\n\n1. Patients with advanced HCC who are inoperable and unsuitable for local therapy, and whose disease has progressed or cannot tolerate therapy after first - or second-line therapy, and who meet one of the following requirements: 1) have a histological or cytological diagnosis of HCC; 2) According to the National Health Commission's Guidelines for Primary Liver Cancer Diagnosis and Treatment (2024 edition), the clinical diagnosis was HCC;\n2. At least one measurable lesion was present according to RECIST1.1 and mRECIST criteria;\n3. The expressions of Nectin4, NKG2DL, TROP2, B7H3 and GPC3 in tumor tissues were detected by immunohistochemistry in primary and metastatic specimens or in white paraffin sections of previous pathological pathology (the expression of tumor cells with a target \\>10% is considered positive, and at least 2 targets are required to be positive), as well as the expression of FAP in tumor tissues;\n4. The patient's T cell quality (pre-experimental) assessment met the criteria: at least 5 times T cell proliferation within 3 days, and at least 10% lentivirus transduction efficiency;\n5. ECOG performance status score of 0-2;\n6. Child-Pugh score ≤6;\n7. Expected survival time of at least 3 months;\n8. No contraindications to peripheral blood mononuclear cell (PBMC) collection;\n9. Seven days prior to the first treatment with the study drug, organ function levels must meet the following requirements: Hematology: Hemoglobin (Hb) ≥90 g\u002FL; Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; Platelet count ≥75×10⁹\u002FL. Blood Biochemistry: Serum albumin ≥28 g\u002FL; Total bilirubin ≤2× upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× ULN; Alkaline phosphatase (ALP) ≤3× ULN; Creatinine ≤1.5× ULN. Coagulation Function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN; Activated partial thromboplastin time (APTT) ≤1.5× ULN. Cardiac Function: Echocardiography confirms normal diastolic function; Left ventricular ejection fraction (LVEF) ≥50%; No severe arrhythmia. Pulmonary and Renal Function: No severe lung or kidney disease; No active pulmonary infection; Blood oxygen saturation ≥92% in room air.\n10. Serum pregnancy test results of women of childbearing age must be negative within 7 days before the first use of the study drug; Fertile men or women with the possibility of becoming pregnant must use a highly effective contraceptive method (such as oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicides) throughout the trial and continue contraception for 12 months after the end of treatment;\n11. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion criteria:\n\n1. Uncontrollable active infection (excluding HBV and\u002For HCV infections);\n2. active central nervous system disease, or known concomitant brain metastases with significant neurological\u002Fpsychiatric symptoms assessed by MMSE;\n3. Known allergy to 2 or more non-similar foods\u002Fdrugs, or known allergy to chemotherapy preconditioning drugs (such as cyclophosphamide, fludarabine);\n4. Any toxicity caused by previous antitumor therapy before chemotherapy preconditioning has not returned to grade 1 or below (CTCAE version 5.0);\n5. Patients who have participated in or are participating in clinical trials of other drugs\u002Ftherapies within 4 weeks prior to the first administration of the investigational drug;\n6. Major surgery had been performed\u002Freceived within 4 weeks prior to the first administration of the study drug or had not yet recovered from the side effects of the surgery, live vaccination, and radiotherapy within 2 weeks;\n7. Patients who are taking systemic hormone therapy for immunosuppressive purposes (dose \\>10mg\u002F day prednisone or other equivalent hormone) and continue to use within 2 weeks prior to treatment;\n8. Pregnant or lactating women;\n9. A history of other malignancies within the past 5 years, except cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early prostate cancer, and cervical carcinoma in situ;\n10. Active inflammatory bowel disease or digestive tract ulcer;\n11. HIV antibody or treponema pallidum antibody test results positive;\n12. A large amount of pleural fluid or ascites accompanied by clinical symptoms that require symptomatic treatment;\n13. A history of active lung disease (pneumonia, obstructive pulmonary disease, asthma) or active pulmonary tuberculosis;\n14. suffering from blood system diseases: leukemia, lymph nodes, myelodysplastic syndrome or myeloma;\n15. Except vitiligo accidental immune deficiency disease or autoimmune disease;\n16. Clinically significant bleeding symptoms or definite bleeding tendency occurred within 3 months before recruitment, such as cough\u002Fhemoptysis of 2.5ml or more per day, gastrointestinal bleeding, esophageal varicose veins with bleeding risk, hemorrhagic gastric ulcer or vasculitis. At baseline, if the stool was positive for occult blood, it could be re-examined; if it was still positive, gastroscopy was required; if the gastroscopy indicated severe esophageal and gastric fundus varices, it could not be included in the group (except those who were excluded by gastroscopy within 3 months before enrollment).\n17. Have any clinical problems beyond your control, including but not limited to:\n\n1\\) Persistent or active (severe) infection; 2) poorly controlled hypertension (persistent blood pressure \\>150\u002F90mmHg); 3) Poorly controlled diabetes; 4) Heart disease (Class III\u002FIV congestive heart failure or heart block as defined by the Heart Society of New York); 5) The following conditions occurred within 6 months before the first medication: deep vein thrombosis or pulmonary embolism; Myocardial infarction; Severe or unstable arrhythmia or angina; Percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; Cerebrovascular accident, transient ischemic attack, cerebral embolism.\n\n18.have obvious genetic diseases; 19. have received a stem cell transplant or an organ transplant; 20.Those who have a history of psychotropic drug abuse and cannot quit or have a history of mental disorders; 21.other severe, acute, or chronic medical conditions or abnormalities in laboratory tests that the investigator determines may increase the risks associated with participation in the study or may interfere with the interpretation of the study results; 22.Patients who were judged by the investigator to have poor compliance or other conditions that made them unfit to participate in the trial.",{"count":132,"type":21},[59,24],"This study is a prospective, single-arm, open, single-center clinical trial initiated by the investigator. The principal investigators are professors Shen Feng and Zhang Xiaofeng from The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital).\n\nPrimary Objectives:\n\n1. To evaluate the safety and tolerability of super Hi-TCR-T cells targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP in the treatment of refractory\u002Frecurrent advanced hepatocellular carcinoma (HCC) and other solid tumors.\n2. To assess the efficacy of super Hi-TCR-T cells targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP in the treatment of refractory\u002Frecurrent advanced HCC and other solid tumors, focusing on progression-free survival (PFS).\n\nSecondary Objectives:\n\n1. To evaluate the efficacy of super Hi-TCR-T cells targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP in the treatment of refractory\u002Frecurrent advanced HCC and other solid tumors at 1, 3, 6, and 12 months, assessing disease control rate (DCR: CR+PR+SD), time to progression (TTP), and overall survival (OS).\n2. To observe and assess the quality of life (QOL score) of patients receiving super Hi-TCR-T cell therapy targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP for refractory\u002Frecurrent advanced HCC and other solid tumors.\n\nExploratory Objectives:\n\n1. To evaluate the relationship between the in vivo expansion and persistence of super Hi-TCR-T cells targeting Nectin4\u002FNKG2DL\u002FTROP2\u002FB7H3\u002FGPC3\u002FFAP and disease progression.\n2. To explore potential predictive biomarkers. Thirty patients are planned to be recruited for this study. The subjects were advanced HCC patients who had failed second-line therapy or could not tolerate therapy. The expression levels of Nectin4, NKG2DL, TROP2, B7H3, GPC3 and FAP were detected by immunohistochemistry in the pathologic tissues of the primary and metastatic sites. Meanwhile, 20ml peripheral blood was extracted to evaluate the quality of T cells (in vitro proliferation activity and lentiviral transduction efficiency). Patients with positive expression rates of at least 2 targets (excluding FAP) \\>10% and qualified T cell quality could be considered for inclusion.\n\nPeripheral blood lymphocytes were collected and Hi-TCR-T cells targeting three targets (including FAP) were prepared. After pretreatment with fludarabine + cyclophosphamide chemotherapy (FC regimen), the prepared Hi-TCR-T cells were transfused back, in which the dose of Hi-TCR-T cells at each target was 3.0x106 cells\u002Fkg body weight (the dose was the extended therapeutic dose obtained in the previous clinical trial), and the drug was administered by peripheral intravenous infusion. To improve efficacy, Hi-TCR-T cell retransfusion can be prepared by increasing the cell dose of the target or changing the combination of the target as the disease progresses and evaluated by a multidisciplinary team (MDT).\n\nSafety and efficacy evaluation and exploratory studies were conducted after reinfusion of Hi-TCR-T cells from screening multiple targets:\n\n1. Safety assessment: at baseline, 4, 7, 10, 2, 3, 4, 8, 12, 16, 20, 6, 9 and 12 months after cell therapy;\n2. Effectiveness evaluation: at baseline, 4, 12, 6, 9, 12, 24, and 36 months after cell therapy. Safety assessment: At baseline, 4, 7, 10, 2, 3, 4, 8, 12, 16, 20, 6, 9, and 12 months after cell therapy;\n3. Exploratory study: 20ml peripheral blood was collected from patients at baseline, 7 days, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 6 months, 9 months, 12 months after cell therapy, to explore the relationship between the proliferation and survival time of Hi-TCR-T cells in vivo and the changes of disease and peripheral blood cytokines.\n\nThe start time of the study was defined as the date the first patient was enrolled; The end time of the study was defined as 12 months after the end of medication for the final patient, or all patients died, or all patients had lost follow-up or withdrawn consent (whichever occurred first). The planned recruitment period is 12-18 months.",[27],[289,290],"Hi-TCR-T","Advanced hepatocellular carcinoma",{"date":292,"type":39},"2025-09-03",{"date":294,"type":39},"2025-07-30",{"date":296,"type":21},"2028-04-07",{"name":298,"class":46},"Eastern Hepatobiliary Surgery Hospital",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":78},"100602441","phase-1-autologous-neoantigen-specific-t-cell-therapy-for-advanced-hepatocellular-carcinoma-100602441","NCT07123545","Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma","Feasibility, Safety and Efficacy Study of Autologous Neoantigen-Specific T-Cell Therapy (iNeo-Vac-T01) in Advanced Hepatocellular Carcinoma Patients","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive)\n2. Histologically confirmed advanced hepatocellular carcinoma (HCC) with:\n\n\u003C!-- -->\n\n1. Radiologically measurable disease per RECIST v1.1\n2. Documented progression on ≥2 prior lines of systemic therapy 3.Life expectancy ≥6 months 4.ECOG performance status 0 or 1 5.Available archival or fresh tumor tissue sufficient for comprehensive genomic profiling OR existing whole-genome sequencing (WGS), whole-exome sequencing (WES), or RNA-sequencing data meeting prespecified quality thresholds 6.Adequate organ and marrow function:\n\n(1)Hematologic:\n\n1. White blood cell count (WBC) ≥3.0 × 10⁹\u002FL\n2. Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL\n3. Hemoglobin ≥9.0 g\u002FdL (≥5.6 mmol\u002FL)\n4. Platelet count ≥100 × 10⁹\u002FL (2)Hepatic:\n\na.Total bilirubin ≤1.5 × upper limit of normal (ULN) (≤3 × ULN if liver metastases present) b.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN (≤5 × ULN if liver metastases present) (3)Renal:\n\n1. Serum creatinine ≤1.5 × ULN OR\n2. Calculated creatinine clearance (CrCl) ≥50 mL\u002Fmin (Cockcroft-Gault formula) (4)Coagulation:\n\n\u003C!-- -->\n\n1. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN AND activated partial thromboplastin time (aPTT) ≤1.5 × ULN (unless receiving therapeutic anticoagulation with stable INR\u002FPT\u002FaPTT within target range) 7.Reproductive Status:\n\n   1. Women of childbearing potential (WOCBP): Negative serum pregnancy test within 7 days prior to treatment initiation AND agreement to use highly effective contraception during study participation and for ≥120 days after last study intervention\n   2. Men: Agreement to use barrier contraception during study participation and for ≥120 days after last study intervention 8.Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n\n   Exclusion Criteria:\n\n   1.History of other active malignancies within the past 5 years, except:\n   1. Adequately treated basal cell or squamous cell skin cancer\n   2. Carcinoma in situ of the cervix\n   3. Other malignancies considered cured with minimal risk of recurrence (e.g., localized thyroid cancer) 2.Failure to identify therapeutically targetable neoantigens via genomic analysis 3.Prior allogeneic bone marrow, solid organ, or hematopoietic stem cell transplantation 4.Active or symptomatic central nervous system (CNS) metastases except:\n\n   (1)Previously treated CNS metastases that are radiologically stable (no evidence of progression) for ≥4 weeks and (2)Asymptomatic and off corticosteroid\u002Fanticonvulsant therapy for ≥4 weeks prior to enrollment (3)Note: Leptomeningeal disease is excluded regardless of stability or treatment status.\n\n   5.Active bacterial, fungal, or mycobacterial infection requiring systemic therapy (including untreated latent tuberculosis) 6.Active viral infections meeting any of the following:\n   1. Detectable HBV DNA (if HBsAg positive or HBcAb positive)\n   2. Detectable HCV RNA\n   3. HIV infection (serologically confirmed)\n   4. Active syphilis infection (serologically confirmed) 7.Active autoimmune disease requiring systemic immunosuppressive therapy (\\>10 mg prednisone equivalent daily) within the past 2 years, except:\n\n   \u003C!-- -->\n\n   1. Vitiligo\n   2. Type 1 diabetes mellitus\n   3. Hypothyroidism stable on hormone replacement\n   4. Psoriasis not requiring systemic therapy 8.Systemic immunosuppressive therapy (\\>10 mg prednisone equivalent per day) within 14 days prior to planned cell infusion (topical, inhaled, or ophthalmic corticosteroids are permitted) 9.Uncontrolled intercurrent illness including, but not limited to:\n\n   (1)New York Heart Association (NYHA) Class III or IV congestive heart failure (2)Unstable angina pectoris (3)Uncontrolled cardiac arrhythmia (4)Uncontrolled hypertension (≥160\u002F100 mmHg despite medication) (5)Clinically significant pulmonary disease 10.History of substance abuse or psychiatric\u002Fsocial condition that would impair ability to provide informed consent or comply with study requirements 11.History of severe (Grade ≥3) hypersensitivity reactions to vaccine components or investigational products, or any condition deemed by the investigator to pose an unacceptable risk for immunotherapy 12.Any condition that, in the opinion of the Investigator, would compromise patient safety or interfere with study participation or interpretation of results",{"count":307,"type":21},20,[59,24],"The goal of this open-label, single-arm phase I\u002FII clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced hepatocellular carcinoma who have failed second-line or later systemic therapies.",[27],"2025-08-13",{"date":313,"type":39},"2025-08-14",{"date":315,"type":39},"2025-08-01",{"date":317,"type":21},"2029-07-31",{"name":206,"class":46},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":326,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":78},"100592567","phase-1-personalized-tumor-neoantigen-mrna-therapy-for-advanced-hepatocellular-carcinoma-100592567","NCT06995105","Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma","Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen mRNA Therapy Combined With PD-1 Monoclonal Antibody and TACE for Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* (1) Subjects who meet all the following inclusion criteria will enter the pre-screening stage of this study and undergo the lesion puncture process:\n\n  1. Voluntarily sign the informed consent form;\n  2. Aged ≥18 years and ≤75 years, regardless of gender;\n  3. Strictly meet the 2018 American Association for Clinical Diagnosis of Liver Diseases (AASLD) clinical diagnostic criteria for HCC, and imaging assessment is unresectable\u002Fmetastatic hepatocellular carcinoma (HCC), CNLC stage Ib to IIIb;\n  4. Have not received systemic or local treatment for HCC in the past.\n  5. According to the solid tumor efficacy evaluation criteria (RECIST 1.1), the investigators assess the presence of measurable lesions.\n  6. Child-Pugh score within 7 points (including 7 points)\n  7. Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;\n  8. Adequate fresh tumor tissue samples can be obtained for exome and transcriptome sequencing analysis;\n  9. The main organ functions of the heart, liver and kidney are normal:\n\n     1. QTc (corrected QT interval) in the electrocardiogram: ≤450 milliseconds for men, or ≤470 milliseconds for women;\n     2. Coagulation function: international normalized ratio (INR) ≤1.5×ULN; activated partial thromboplastin time (APTT) ≤1.5 times ULN;\n     3. Hematological indicators: white blood cells ≥3.5×109\u002FL; absolute neutrophil count (ANC) ≥1.5×109\u002FL; hemoglobin (HGB) ≥10 g\u002FdL; platelet count (PLT) ≥80×109\u002FL;\n     4. Biochemical indicators: serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN (ALT or AST ≤ 5 times ULN is allowed for patients with liver metastasis and liver cancer); serum creatinine and urea nitrogen ≤ 1.5 times ULN;\n  10. Male patients with fertility and female patients of childbearing age agree to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last administration of the trial drug; women of childbearing age include premenopausal women and women within 2 years after menopause;\n  11. Able to follow the study protocol and follow-up process.\n\n  (2) Subjects who meet all the following inclusion criteria will enter the formal screening phase of this study and enter the study medication process:\n  1. Voluntarily sign the informed consent form;\n  2. Aged ≥18 years and ≤75 years, regardless of gender;\n  3. Primary hepatocellular carcinoma confirmed by pathology (histology or cytology);\n  4. Have not received any systemic treatment.\n  5. According to the solid tumor efficacy evaluation criteria (RECIST 1.1), the researcher assesses the presence of measurable lesions.\n  6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n  7. Normal function of the heart, liver and kidney:\n\n     1. QTc (corrected QT interval) in the electrocardiogram: ≤450 milliseconds for men, or ≤470 milliseconds for women;\n     2. Coagulation function: international normalized ratio (INR) ≤1.5×ULN; activated partial thromboplastin time (APTT) ≤1.5 times ULN;\n     3. Hematological indicators: white blood cells ≥3.5×109\u002FL; absolute neutrophil count (ANC) ≥1.5×109\u002FL; hemoglobin (HGB) ≥10 g\u002FdL; platelet count (PLT) ≥80×109\u002FL;\n     4. Biochemical indicators: serum total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN (ALT or AST ≤ 5 times ULN is allowed for patients with liver metastasis and liver cancer); serum creatinine and urea nitrogen ≤ 1.5 times ULN;\n  8. Male patients with fertility and female patients of childbearing age agree to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last administration of the trial drug; women of childbearing age include premenopausal women and women within 2 years after menopause;\n  9. Able to follow the study protocol and follow-up process.\n\n     Exclusion Criteria:\n* 1\\) Diffuse HCC. 2) Known fibrolamellar HCC, cholangiocarcinoma, and mixed HCC. 3) Concomitant tumor thrombus in the main portal vein or contralateral portal vein, superior mesenteric vein, or vena cava.\n\n  4\\) History of meningeal disease; presence of central nervous system metastases or meningeal metastases.\n\n  5\\) History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, or idiopathic pneumonia, or evidence of active pneumonia on screening chest CT.\n\n  6\\) Patients with other malignant tumors at the same time, but basal cell carcinoma, thyroid cancer, cervical atypical hyperplasia, etc. that have been cured, have been in a disease-free state for more than 5 years or are considered by researchers to be less likely to relapse; 7) Patients with a history of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation; 8) Patients with immunosuppressants, that is, those who need to take immunosuppressants regularly 4 weeks before the screening period and during the clinical study, including but not limited to the following: those with severe asthma, autoimmune diseases or immunodeficiency, those who are treated with immunosuppressive drugs, and those with a known history of primary immunodeficiency; but excluding type 1 diabetes, autoimmune-related hypothyroidism requiring hormone treatment, and vitiligo and psoriasis that do not require systemic treatment; 9) Active bacterial or fungal infection confirmed by clinical diagnosis; active tuberculosis or history of tuberculosis; 10) Those with positive human immunodeficiency virus (HIV) antibody test, positive Treponema pallidum (TP) antibody test, active hepatitis C (positive hepatitis C virus (HCV) antibody and HCV RNA result is positive), active hepatitis B; 11) Herpes virus infection (except for those with scabs for more than 4 weeks); respiratory virus infection (except for those who have recovered for more than 4 weeks); 12) Uncontrolled complications include but are not limited to active infection, symptomatic congestive heart failure, unstable angina, arrhythmia; severe coronary artery disease or cerebrovascular disease, or other diseases that the investigators believe are not suitable for inclusion; 13) History of drug abuse, clinical, psychological or social factors that affect informed consent or research implementation; history of mental illness; 14) History of food, drug or vaccine allergy, or other potential immunotherapy allergies considered by the investigator.\n\n  15\\) Pregnant or lactating women; 16) Those who the investigators believe are not suitable for inclusion or may not be able to complete this trial for other reasons.",{"count":132,"type":21},[59,24],"This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients with advanced hepatocellular carcinoma.",[27],"2025-05-20",{"date":332,"type":39},"2025-05-29",{"date":334,"type":39},"2025-04-09",{"date":336,"type":21},"2028-04-01",{"name":206,"class":46},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":78},"100573699","effect-of-prehabilitation-during-the-conversion-therapy-on-postoperative-outcomes-in-unresectable-hepatocellular-carcinoma-100573699","NCT06749678","Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma","Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Patients With Unresectable Hepatocellular Carcinoma: a Prospective, Open, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients must be aged between 18 and 75 years, inclusive, with no gender restrictions.\n2. Patients must have an initial diagnosis of unresectable hepatocellular carcinoma (HCC) confirmed by EASL\u002FAASLD diagnostic criteria, pathological histology, or cytology, and must be planned for conversion therapy.\n3. Patients must have an American Society of Anesthesiologists (ASA) physical status classification of ≤III.\n4. Patients must be physically capable of participating in exercise training, defined as the ability to walk continuously on flat ground for more than 200 meters without rest and to climb two flights of stairs consecutively without requiring a break.\n5. Patients must not have any psychiatric disorders, speech impediments, or consciousness disturbances, and must possess adequate comprehension, communication, and literacy skills.\n6. Patients must voluntarily enroll in the study, be able to provide written informed consent, and be capable of understanding and adhering to the trial protocol and follow-up procedures.\n\n   \\-\n\nExclusion Criteria:\n\n1. A known diagnosis of cholangiocarcinoma, sarcomatoid hepatocellular carcinoma (HCC), combined hepatocellular carcinoma, or fibrolamellar carcinoma.\n2. Presence of extrahepatic metastases or concurrent other malignant tumors.\n3. Presence of psychiatric disorders or cognitive impairments that would impede compliance with study requirements.\n4. Unsuitability for participation in exercise training due to skeletal muscle diseases or a history of fracture within the past 6 months.\n5. Pregnant or breastfeeding women.\n6. Individuals with severe and irreversible cardiac, pulmonary, or renal organic diseases, or severe anemia, which would make them unsuitable for preoperative rehabilitation programs. -",{"count":346,"type":21},84,[192],"This is a prospective, randomised controlled clinical trial to study the impact of prehabilitation on postoperative complications, physical function, quality of life, and short-term survival outcomes in patients with unresectable liver cancer undergoing conversion therapy.",[27,350],"Prehabilitation",[352,353,354],"unresectable hepatocellular carcinoma","prehabilitation","conversion therapy","2024-12-24",{"date":357,"type":39},"2024-12-27",{"date":359,"type":21},"2025-01-01",{"date":361,"type":21},"2027-06-01",{"name":363,"class":46},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]